Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1)

Figure 1

ISS before and after treatment for (a) IGF1 treated and (b) untreated patients. The Mean change in ISS in IGF1 treated versus untreated patients (, Mann-Whitney test, two-tailed). The change in ISS for the treated group was short of significance (, Wilcoxon Signed Ranks Test, two-tailed). ISS: International Scoring System. S1–10: treated patients 1–10; U2–10: untreated patients 1–10.

(a)

(b)